Swami Rama Himalayan University, Himalayan Institute of Medical Sciences, Department of Pathology - Dehradun, India.
Swami Rama Himalayan University, Himalayan Institute of Medical Sciences, Department of Surgery - Dehradun, India.
Rev Assoc Med Bras (1992). 2024 Aug 16;70(7):e20240173. doi: 10.1590/1806-9282.20240173. eCollection 2024.
Tumor budding is a phenomenon in which the tumor cells detach from the main mass and are present at the invasive front. The present study was conducted to study tumor budding in invasive breast carcinoma and to correlate it with clinicopathological parameters and molecular subtypes.
The study was conducted over a period of 1 year, and tumor budding was studied as a single or group of cells at the invasive front of breast carcinoma counted in a high-power field (40×). The grading was statistically correlated with tumor size, grade, lymph node status, lymphovascular invasion, pathological TNM staging, molecular subtype, and survival of patients.
A total of 50 cases of invasive breast carcinoma were included, out of which 66% (n=33) showed high-grade tumor budding, which was statistically significantly higher in grade 2 invasive ductal carcinoma (p<0.05). High tumor budding was associated with lymphovascular invasion, lymph node metastasis, and a high Ki-67 proliferative index. All cases showing low-grade budding were alive until 6 months of diagnosis, but there was no statistically significant association between stage and budding.
Tumor buds are significantly higher in grade 2 invasive ductal carcinoma with lymphovascular invasion, lymph node metastasis, and a high Ki-67 proliferative index. Immunohistochemistry may prove helpful in distinguishing tumor buds from their mimickers. Further studies with extended follow-up are recommended to predict tumor budding as a prognostic marker in breast carcinoma, which may play an important role in cancer therapy.
肿瘤芽生是指肿瘤细胞从主体脱落并出现在浸润前沿的现象。本研究旨在研究浸润性乳腺癌中的肿瘤芽生，并将其与临床病理参数和分子亚型相关联。
本研究在一年内进行，通过在高倍镜（40×）下计数乳腺癌浸润前沿的单个或成簇的肿瘤芽生细胞来进行研究。对肿瘤芽生的分级与肿瘤大小、分级、淋巴结状态、脉管侵犯、病理 TNM 分期、分子亚型和患者生存进行统计学相关性分析。
共纳入 50 例浸润性乳腺癌病例，其中 66%（n=33）显示高等级肿瘤芽生，2 级浸润性导管癌中统计学上显著更高（p<0.05）。高肿瘤芽生与脉管侵犯、淋巴结转移和高 Ki-67 增殖指数相关。所有显示低等级芽生的病例在诊断后 6 个月内均存活，但分期与芽生之间无统计学显著关联。
肿瘤芽生在伴有脉管侵犯、淋巴结转移和高 Ki-67 增殖指数的 2 级浸润性导管癌中显著更高。免疫组织化学可能有助于区分肿瘤芽生与其他类似物。建议进行进一步的研究并延长随访时间，以预测肿瘤芽生作为乳腺癌的预后标志物，这可能在癌症治疗中发挥重要作用。
